Analysis of HBsAg levels, HBsAg immune complexes, HBV pregenomic RNA andHBcrAg dynamics during and after NAP-based combination therapy in the REP301-LTF and REP 401 studies
EASL 2020 Aug 27-29 virtual - see LBP below following announcement
Replicor announces presentation of experimental endpoint data at EASLMONTREAL, September 10th, 2020 - Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the late breaking presentation of experimental endpoint data from its most recent REP 301/301-LTF and REP 401 studies at the Digital ILC 2020.
Conducted in collaboration with Abbott Diagnostics, a variety of experimental virologic markers were analyzed during therapy and follow-up after treatment with NAP-based combination therapy in HBeAg HBV / HDV co-infection (REP 301/301-LTF) and HBeAg negative HBV infection (REP 401). These included ultralow HBsAg (<0.005 IU/mL), HBV pgRNA, HBcrAg and HBsAg immune complexes..
During NAP-based therapy, HBsAg clearance was shown to extend to < 0.005 IU/mL with clearance of both HBV RNA and HBcrAg. All of these experimental milestones were maintained in patients with functional cure of HBV. HBsAg immune complexes declined early in therapy and this decline generally continued throughout therapy and universally during follow-up in participants with functional cure..
Replicor's CSO, Dr. Andrew Vaillant commented, "These experimental endpoint data demonstrate not only the very effective nature of HBsAg clearance with NAP-based therapy, but also the effective silencing and or erosion of cccDNA. They also demonstrate the profound control of infection in patients that achieve functional cure with NAPs. We are also very encouraged by the absence of HBsAg immune complexes in participants with functional cure, which strongly suggests the efficient removal of integrated HBV DNA from the liver.".
Replicor's presentation is available on the company's website at www.replicor.com/science/conference-presentations. For further information about the Digital ILC 2020: https://ilc-congress.eu/ .
About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com..
Ongoing analysis of virologic control / functional cure of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 3.5-year follow-up results from the REP 301-LTF study .
Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection.
Analysis of HBsAg levels, HBsAg immune complexes, HBV pregenomic RNA andHBcrAg dynamics during and after NAP-based combination therapy in the REP301-LTF and REP 401 studies..
M. Bazinet1, M Anderson2, V. Pântea3, G. Placinta3, I. Moscalu4, V. Cebotarescu3, L. Cojuhari3, P. Jimbei5, L.Iarovoi3, V. Smesnoi5, T. Musteata5, A. Jucov3,4, J. Gersch2, V. Holzmayer2, M. Kuhns2, G. Cloherty2, A. Vaillant11. Replicor Inc. Montreal, Canada, 2. Abbott Diagnostics, Abbott Park, Illinois, USA, 3. Department of Infectious Diseases, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, 4. ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chisinau, Republic of Moldova, 5. Toma Ciorba Infectious Clinical Hospital, Chisinau, Republic of Moldova
